Metastatic Renal Cell Carcinoma Risk According to Tumor Size Journal Article


Authors: Thompson, R. H.; Hill, J. R.; Babayev, Y.; Cronin, A.; Kaag, M.; Kundu, S.; Bernstein, M.; Coleman, J.; Dalbagni, G.; Touijer, K.; Russo, P.
Article Title: Metastatic Renal Cell Carcinoma Risk According to Tumor Size
Abstract: Purpose: Recent evidence suggests significantly discordant findings regarding tumor size and the metastasis risk in renal cell carcinoma cases. We present our experience with renal cell carcinoma. We evaluated the association between tumor size and the metastasis risk in a large patient cohort. Materials and Methods: Using our prospectively maintained nephrectomy database we identified 2,691 patients who were treated surgically for a sporadic renal cortical tumor between 1989 and 2008. Associations between tumor size and synchronous metastasis at presentation (M1 renal cell carcinoma) were evaluated with logistic regression models. Metastasis-free survival after surgery was estimated using the Kaplan-Meier method in 2,367 patients who did not present with M1 renal cell carcinoma and were followed postoperatively. Results: Of the 2,691 patients 162 presented with metastatic renal cell carcinoma. Only 1 of 781 patients with a tumor less than 3 cm had M1 renal cell carcinoma at presentation and tumor size was significantly associated with metastasis at presentation (for each 1 cm increase OR 1.25, p <0.001). Of the 2,367 patients who did not present with metastasis metastatic disease developed in 171 during a median 2.8-year followup. In this group only 1 of the 720 patients with renal cell carcinoma less than 3 cm showed de novo metastasis during followup. Metastasis-free survival was significantly associated with tumor size (for each 1 cm increase HR 1.24, p <0.001). Conclusions: In our experience tumor size is significantly associated with synchronous and asynchronous metastases after nephrectomy. Our results suggest that the risk of metastatic disease is negligible in patients with tumors less than 3 cm. © 2009 American Urological Association.
Keywords: controlled study; treatment outcome; survival analysis; cancer surgery; major clinical study; mortality; cancer risk; chemotherapy, adjuvant; combined modality therapy; follow up; neoplasm staging; sensitivity and specificity; prospective studies; metastasis; odds ratio; age factors; medical record review; kidney carcinoma; kidney neoplasms; nephrectomy; risk assessment; kaplan-meiers estimate; confidence intervals; carcinoma, renal cell; tumor burden; cancer size; carcinoma; neoplasm metastasis; new york city; neoplasm invasiveness; sex factors; databases, factual; renal cell; asynchronous metastasis; synchronous metastasis
Journal Title: Journal of Urology
Volume: 182
Issue: 1
ISSN: 0022-5347
Publisher: Elsevier Science, Inc.  
Date Published: 2009-07-01
Start Page: 41
End Page: 45
Language: English
DOI: 10.1016/j.juro.2009.02.128
PUBMED: 19450840
PROVIDER: scopus
PMCID: PMC2735023
DOI/URL:
Notes: --- - "Cited By (since 1996): 5" - "Export Date: 30 November 2010" - "CODEN: JOURA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jonathan Coleman
    341 Coleman
  2. Paul Russo
    581 Russo
  3. Guido Dalbagni
    325 Dalbagni
  4. Shilajit D Kundu
    9 Kundu
  5. Matthew G Kaag
    32 Kaag
  6. Karim Abdelkrim Touijer
    257 Touijer
  7. Angel M Cronin
    145 Cronin
  8. Jennifer Rebecca Hill
    1 Hill